Figure 1: Comparison of proteolytic digested modified and non-modified T1249. Digestion with endoproteinase Lys-C and subsequent separation with reversed phase HPLC. A) sample 20 kDa PEG-Butanoaldehyde-T1249; B) sample T1249. UV absorbance at 215 nm.





Figure 2: Matrix assisted laser desorption ionization time of flight (MALDI TOF) mass spectrum of the collected HPLC fraction PEG-34 (Figure 1). Spectra were acquired in linear mode with trans-3-indoleacrylic acid as the matrix. Molecular weight in Da.






Figure 3: N-terminal (Edman) sequencing of the collected HPLC fraction PEG-34 (Figure 1).




Figure 4. Concentration-time profile of mPEG $_{20K}$ -CMAB-T1249 in rats after a single subcutaneous administration at 8 mg/kg.




Figure 5. Plasma pharmacokinetics for T-1249 administered by subcutaneous or intravenous injection to rats.





Figure 6.

Effect of T-1249 and PEG - T-1249 on HIV-1 Viral Load in Plasma in SCID Mice After 7 Days of Treatment



DOSE (mg/kg/day - I.P., bld)

* p < 0.05 (vs. saline)

SCID females; 6-8 wk